Sanofi has announced a strategic partnership with Orano Med, a subsidiary of the Orano Group, to accelerate the development of next-generation radioligand therapies (RLTs) aimed at treating rare cancers. This collaboration will leverage the expertise of both companies in biopharmaceuticals and nuclear technology to create a new entity operating under the Orano Med brand, focused on discovering and developing innovative therapies based on lead-212 (212Pb) alpha-emitting isotopes.
As per the press release, the partnership builds on an earlier exclusive licensing agreement between Sanofi, Orano Med, and RadioMedix, which aims to advance RLTs, particularly the late-stage project AlphaMedix™. Targeted alpha therapy uses biological vectors to direct radioisotopes specifically to cancer cells, enhancing the destruction of malignant cells while minimizing damage to healthy tissues. This precision medicine approach seeks to redefine treatment standards for rare cancers, ultimately extending patients’ lives and improving their quality of life.
Paul Hudson, CEO, Sanofi said, “We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive groundbreaking progress in the fight against cancer.” He emphasized Sanofi’s commitment to fostering innovation within France and globally to develop cutting-edge treatments.
Nicolas Maes, CEO, Orano Group stated, “This innovation demonstrates that nuclear technology can positively impact human health, not just energy and climate.”
Sanofi’s investment will enhance Orano Med’s capabilities in developing lead-212 based therapies, supported by the company’s unique industrial platform. This platform ensures a reliable and scalable supply of these therapies, thanks to Orano Med’s extensive stock of raw materials and patented manufacturing processes.
HoumanAshrafian, Sanofi’s Executive Vice President of Research and Development, remarked, “We are thrilled to invest in radioligand therapies, which hold potential for patients suffering from rare cancers.” He acknowledged the promising nature of Orano Med’s lead-212 based technologies.
Julien Dodet, President of Orano Med’s Governing Board, welcomed the partnership, viewing it as a validation of their strategy and expertise in targeted alpha therapies developed over the last 15 years.
Both Sanofi and Orano Med are committed to advancing oncology innovation and are part of the Paris Saclay Cancer Cluster, contributing to France’s ambitious 2030 plan to accelerate advancements in cancer treatment.
